StoneX Group’s aTyr Pharma ATYR Stock Holding History

StoneX Group’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-15,709	Closed	-$27.6K	–	929
2024 Q3	$27.6K	Buy	+15,709	New	+$28.6K	0.01%	334

Other funds holding ATYR

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

StoneX Group's ATYR Position: Q4 2024 in Review

StoneX Group sold out of aTyr Pharma (ATYR) in Q4 2024, closing a stake of 15,709 shares — an estimated $27.6K sold.

StoneX Group first reported a position in ATYR in Q3 2024 and held it in 1 quarter. The position peaked at $27.6K in Q3 2024. 77 funds tracked by Wall St. Rank hold ATYR as of Q4 2024.

StoneX Group reported no remaining aTyr Pharma position as of Q4 2024 after selling out during the quarter.
StoneX Group sold 15,709 aTyr Pharma shares in Q4 2024, an estimated $27.6K.
StoneX Group first reported a position in aTyr Pharma in Q3 2024 and held it in 1 quarter.
StoneX Group's aTyr Pharma position peaked at $27.6K in Q3 2024.
77 funds tracked by Wall St. Rank held aTyr Pharma as of Q4 2024.

Based on StoneX Group's 13F filing for Q4 2024, filed 12 Feb 2025.